Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Veiligheid en werkzaamheid op lange termijn van Odevixibat bij patiënten met het Alagille-syndroom (ASSERT-EXT)

20 oktober 2026 bijgewerkt door: Albireo, an Ipsen Company

Een open-labelonderzoek om de veiligheid en werkzaamheid op lange termijn van Odevixibat (A4250) bij patiënten met het syndroom van Alagille te evalueren (ASSERT-EXT)

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Studie Overzicht

Toestand

Actief, niet wervend

Interventie / Behandeling

Gedetailleerde beschrijving

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

62

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Brussels, België, 1200
        • Cliniques Universitaires Saint-Luc Bruxelles
      • Berlin, Duitsland, 13353
        • Charité - Universitätsmedizin Berlin
      • Hanover, Duitsland, 30625
        • Medizinische Hochschul
      • Tübingen, Duitsland, 72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
      • Bron, Frankrijk, 69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille, Frankrijk
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris, Frankrijk, 75015
        • Hopital Necker Enfants Malades
      • Florence, Italië
        • AOU Meyer
      • Padova, Italië, 35128
        • Azienda Ospedale University
      • Rome, Italië, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Kuala Lumpur, Maleisië, 59100
        • University of Malaya Medical Center
      • Groningen, Nederland, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht, Nederland
        • Wilhelmina Children's Hospital UMCU Utrecht
      • Warsaw, Polen, 04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
      • Istanbul, Turkije (Türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital
      • Birmingham, Verenigd Koninkrijk
        • Birmingham Women's and Children's NHS Foundation Trust
      • London, Verenigd Koninkrijk, SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
    • California
      • San Diego, California, Verenigde Staten, 92123
        • Rady Children's Hospital
      • San Francisco, California, Verenigde Staten, 94158
        • UCSF
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park, New York, Verenigde Staten, 11042
        • Northwell Health System
      • New York, New York, Verenigde Staten, 10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York, New York, Verenigde Staten, 10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx, New York, Verenigde Staten, 10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas, Texas, Verenigde Staten, 75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston, Texas, Verenigde Staten, 77030
        • Texas Children's Hospital
      • San Antonio, Texas, Verenigde Staten, 78215
        • Texas Liver Institute

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.

Odevixibat is a small molecule and selective inhibitor of IBAT.

Andere namen:
  • A4250

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Verandering ten opzichte van de uitgangswaarde bij gelijktijdige medicatie.
Tijdsspanne: Basislijn tot week 12 (cohort 2).
Basislijn tot week 12 (cohort 2).
Verandering ten opzichte van de uitgangswaarde in vetoplosbare vitamineniveaus.
Tijdsspanne: Basislijn tot week 12 (cohort 2).
Basislijn tot week 12 (cohort 2).
Change from baseline in pruritus
Tijdsspanne: Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
Tijdsspanne: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
Tijdsspanne: Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
Tijdsspanne: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Verandering ten opzichte van de uitgangswaarde in serumgalzuurspiegels
Tijdsspanne: Basislijn tot week 72 (cohort 1).
Basislijn tot week 72 (cohort 1).
Verandering ten opzichte van de uitgangswaarde in serumgalzuurspiegels.
Tijdsspanne: Basislijn tot en met week 72 (cohort 1).
Basislijn tot en met week 72 (cohort 1).
Aantal deelnemers met verandering ten opzichte van de uitgangswaarde bij lichamelijk onderzoek
Tijdsspanne: Basislijn tot week 72 (cohort 1).
Basislijn tot week 72 (cohort 1).
Aantal deelnemers met verandering ten opzichte van de uitgangswaarde in vitale functies
Tijdsspanne: Basislijn tot week 72 (cohort 1).
Basislijn tot week 72 (cohort 1).
Verandering ten opzichte van de uitgangswaarde bij gelijktijdige medicatie
Tijdsspanne: Basislijn tot week 72 (cohort 1).
Basislijn tot week 72 (cohort 1).
Verandering ten opzichte van de uitgangswaarde in laboratoriumtestresultaten Farmacokinetische (PK) Cmax [tijdsbestek: dag 1, week 4, week 8 en week 12]
Tijdsspanne: Basislijn tot week 72 (cohort 1).
Basislijn tot week 72 (cohort 1).
Verandering ten opzichte van de uitgangswaarde in de plasmaconcentratie van het onderzoeksgeneesmiddel
Tijdsspanne: Dag 1, week 4, week 8 en week 12 (cohort 1).
Dag 1, week 4, week 8 en week 12 (cohort 1).
Farmacodynamische parameters: Verandering in serumgalzuurspiegels
Tijdsspanne: Basislijn tot week 12 (cohort 2).
Basislijn tot week 12 (cohort 2).
Change from baseline in patient reported and observer reported itching and scratching severity scores
Tijdsspanne: Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
Tijdsspanne: Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
Tijdsspanne: Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
Tijdsspanne: Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
Tijdsspanne: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
Tijdsspanne: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
Tijdsspanne: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 72 (cohort 1).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Ipsen Medical Director, Ipsen

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 september 2021

Primaire voltooiing (Geschat)

15 februari 2027

Studie voltooiing (Geschat)

15 februari 2027

Studieregistratiedata

Eerst ingediend

13 augustus 2021

Eerst ingediend dat voldeed aan de QC-criteria

1 september 2021

Eerst geplaatst (Werkelijk)

5 september 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

23 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

20 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD-tijdsbestek voor delen

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD-toegangscriteria voor delen

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren